Trial Outcomes & Findings for Predicting Inflammatory Skin Disease Response to IL-23 Blockade (NCT NCT04541329)

Last Updated: 2024-04-30

Results Overview

Psoriasis Area and Severity Index (PASI) is a measure of psoriasis severity. The maximum score is 72, minimum score is 0. The higher the number, the more severe the psoriasis is.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

7 participants

Primary outcome timeframe

baseline and 3 months

Results posted on

2024-04-30

Participant Flow

Participant milestones

Participant milestones
Measure	Tildrakizumab Treatment Tildrakizumab: IL-23 inhibitor
Overall Study STARTED	7
Overall Study COMPLETED	7
Overall Study NOT COMPLETED	0

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Race and Ethnicity were not collected from any participant.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Tildrakizumab Treatment n=7 Participants Tildrakizumab: IL-23 inhibitor
Age, Categorical <=18 years	0 Participants n=7 Participants
Age, Categorical Between 18 and 65 years	7 Participants n=7 Participants
Age, Categorical >=65 years	0 Participants n=7 Participants
Age, Continuous	37 years n=7 Participants
Sex: Female, Male Female	3 Participants n=7 Participants
Sex: Female, Male Male	4 Participants n=7 Participants
Region of Enrollment United States	7 Participants n=7 Participants
Psoriasis Area and Severity Index (PASI) Score	10.7 units on a scale STANDARD_DEVIATION 3.6 • n=7 Participants

PRIMARY outcome

Timeframe: baseline and 3 months

Population: treated patients

Psoriasis Area and Severity Index (PASI) is a measure of psoriasis severity. The maximum score is 72, minimum score is 0. The higher the number, the more severe the psoriasis is.

Outcome measures

Outcome measures
Measure	Tildrakizumab Treatment n=7 Participants Tildrakizumab: IL-23 inhibitor
Psoriasis Area and Severity Index (PASI) Score	3.9 score on a scale Standard Deviation 4.1

Adverse Events

Tildrakizumab Treatment

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Adverse event data not reported

Additional Information

Raymond Cho, MD, PhD

University of California, San Francisco

Phone: 415 353 7800

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee
Publication restrictions are in place